Nuria Ajenjo

Nuria Ajenjo has extensive experience in cancer research and pharmacology, currently serving as part of the CNIO-Spanish National Biobank Network and the Experimental Therapeutics Program at CNIO since May 2009, focusing on anti-cancer drug discovery and molecular pharmacology. Previously, Nuria worked as a researcher at Projech, where efforts centered on anti-obesity drug screening and adipocyte regulation. Prior roles at CNIO and EMBL involved research on cell cycle regulation and signaling pathways related to cancer. Early career experience includes postdoctoral fellowships at the University of Cantabria, where research revolved around cartilage viability and interactions between proto-oncogen c-Myc and tumor suppressor p53, as well as studies on Ras signaling at Centro de Investigación del Cancer. Nuria holds a PhD in Biological Sciences from the University of Cantabria and a Bachelor's degree in Biochemistry from the University of Oviedo.